Lercanidipin Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in arterial smooth muscle. This inhibition prevents calcium‑induced contraction, causing vasodilation of peripheral arteries, lowering systemic vascular resistance and thereby reducing systolic and diastolic blood pressure.

The dose of lercanidipine is individualized by the prescribing healthcare professional based on the patient’s blood pressure, response, and tolerability. The prescriber determines the appropriate strength and dosing schedule.

Safety of lercanidipine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother blood‑pressure control with a lower incidence of reflex tachycardia, but individual response varies and choice depends on clinician judgment.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

Lercanidipin Actavis is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, though rare, include severe hypotension, angio‑edema, and hepatic dysfunction. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, swelling of the face or throat, or signs of liver injury such as jaundice.

Lercanidipine is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation, and in those with severe aortic stenosis or unstable angina. Caution is also advised for patients with significant liver impairment.